Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.…
Positive Trial Results Could Be A Big Moment For Beam Therapeutics (BEAM)
Beam Therapeutics (NASDAQ: BEAM) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 557 employees.
The shares were at 20.90 USD on 20 November 2026, down 5.9% over 52 weeks. Its 52-week range is 20.23 USD to 38.26 USD: the price is 45.4% below the high and 3.3% above the low.
Its market capitalisation is 2.16B USD.
Beam Therapeutics reports return on equity of -6.5%, an operating margin of -267.7% and revenue down 96.8% year over year.
It holds more cash than debt, a net cash position of 800.00M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 13 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 49.85 USD is 138.5% above the current price. The next earnings report is expected on 23 February 2027.